Prospects for PLD Inhibition in Cancer and Thrombotic Disease

Area of Science:

• Biochemistry
• Cell Biology
• Pharmacology

Background:

• Phospholipase D1 and D2 (PLD1/PLD2) are key enzymes in mammalian signaling pathways.
• These enzymes generate phosphatidic acid (PA), a crucial second messenger lipid.
• PLD1/PLD2 are implicated in diverse physiological and pathological processes, including platelet activation, cardiac ischemia, viral infections, neurodegenerative diseases, and cancer.

Purpose of the Study:

• To review the established functions of PLD1 and PLD2.
• To explore the therapeutic potential of targeting PLD1 and PLD2, particularly in thrombotic disease and cancer.
• To discuss ongoing research in developing small molecule inhibitors for PLD enzymes.

Main Methods:

• Review of existing literature on PLD1 and PLD2 functions.
• Analysis of cell biological and animal disease models.
• Examination of therapeutic strategies targeting PLD enzymes.

Main Results:

• PLD1 and PLD2 play significant roles in various cellular signaling events.
• Evidence suggests PLD1/PLD2 involvement in conditions such as thrombosis and cancer.
• Small molecule inhibitors targeting PLD are under development.

Conclusions:

• PLD1 and PLD2 are critical signaling enzymes with broad physiological relevance.
• Thrombotic diseases and cancer represent promising therapeutic areas for PLD inhibition.
• Further development of small molecule PLD inhibitors is warranted for clinical applications.